IGF1 and neoplasm: Comparatively, the efficacy of pegvisomant ranged from about 75 to 97 %, octreotide from about 65 to 79 %, and lanreotide from about 50 to 76 % for a variety of efficacy measures including, but not limited to, reducing serum GH, normalizing IGF-1, and reducing tumor size.